Spironolactone treatment for dermatologic indications is not associated with hypotension in a single-center retrospective study

J Am Acad Dermatol. 2024 Jun;90(6):1245-1247. doi: 10.1016/j.jaad.2024.01.057. Epub 2024 Mar 12.

Authors

Rachel C Hill¹, Yu Wang², Bilal Shaikh³, Michael Ong¹, Paul J Christos³, Shari R Lipner⁴

Affiliations

¹ Weill Cornell Medical College, New York, New York.
² Department of Dermatology, Wake Forest School of Medicine, Wake Forest, North Carolina.
³ Division of Biostatistics, Department of Population Health Sciences, Weill Cornell Medicine, New York, New York.
⁴ Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address: [email protected].

PMID: 38483433
PMCID: PMC11096061 (available on 2025-06-01)
DOI: 10.1016/j.jaad.2024.01.057

No abstract available

Keywords: acne; blood pressure monitoring; dermatology; hair loss; hirsutism; hypotension; medical dermatology; spironolactone.

Publication types

Letter

MeSH terms

Adult
Aged
Female
Humans
Hypotension* / chemically induced
Male
Middle Aged
Mineralocorticoid Receptor Antagonists / adverse effects
Mineralocorticoid Receptor Antagonists / therapeutic use
Retrospective Studies
Skin Diseases / drug therapy
Spironolactone* / adverse effects
Spironolactone* / therapeutic use

Grants and funding

UL1 TR002384/TR/NCATS NIH HHS/United States